North America Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN, Antisense, and Other), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others)

North America Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN, Antisense, and Other), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations)

The genome editing market in North America is expected to grow from US$ 2,136.41 million in 2021 to US$ 7,024.71 million by 2028; it is estimated to grow at a CAGR of 18.5% from 2021 to 2028. Over the past few years, advances in genome editing technologies have been making constant headlines. Genome editing technologies can alter biological research and significantly impact human health, food security, and environmental sustainability as they are precise, relatively inexpensive, easy to use, and remarkably powerful. The introduction of CRISPR-Cas9—a genome-editing tool that can be used to make precise and targeted changes in the DNA sequence with ease—is mainly responsible for the recent rise in the amount and scope of applications of genome editing technologies. The CRISPR platform's ease of use, as compared to previous technologies, has resulted in its widespread adoption and application. Genome editing has a favorable impact on sustainable development, environmental management, food security, and the introduction of affordable diagnostics and therapies for various diseases due to various advancements. A team from MIT and Harvard's Broad Institute has developed a novel CRISPR genome-editing technique that has the potential to fix up to 89% of disease-causing genetic abnormalities. CRISPR-Cas9 and reverse transcriptase, two of the most significant proteins in molecular biology, have been merged into a single machine by researchers. Prime editing is a method that can alter human cells directly in a precise, efficient, and highly versatile manner. They have also developed a CRISPR RNA-cutting enzyme into an antiviral agent that can be programmed to detect and eliminate RNA-based viruses in human cells. The Cas13 enzyme has previously been used to cut and alter human RNA and as a diagnostic approach for detecting the presence of viruses, bacteria, and other targets. This is one of the first studies to use Cas13, or any CRISPR system, as an antiviral in human cells in culture. Further, recognizing the potential of genome editing techniques for studying and manipulating the genome, the DBT has been fostering research and innovation in genome engineering technologies and applications to make them more accessible and inexpensive for research & development. Despite contributing to one-third of all deaths worldwide, there is no effective treatment, to date, for fibrosis. Studies has established PAI-1 as a novel drug target, and pharmacologically targeting this protein may be an effective treatment for combating fibrosis. These factors for CRISPR system research are increasing the market growth.

In the North American region, the US was profoundly affected by the outbreak of the COVID-19 pandemic. The country has marked the highest number of positive patients. Across the nation, various healthcare research centers were working only on COVID-19 therapeutics. As the crisis moved forward, healthcare professionals realized that developing novel therapies using innovative technologies is essential to mitigate this unprecedented crisis. The lack of definitive therapy offers significant opportunities for the genome editing-related market as US FDA has recently approved the use of plasma therapy for critically ill COVID 19 patients. Upcoming stem cell therapies to boost patients' immune systems and eliminate the virus offer significant growth prospects for the market. For instance, Lattice Biologics, in collaboration with Alumina Partners, has been accelerating phase 1 clinical trials for its stem cell-based AminioBoost therapies of COVID-19. Moreover, the mRNA-based vaccines against the COVID-19 had been given emergency use authorization by the regulatory agencies in the region. The active involvement of the government and the associated market players in exploring opportunities for genome editing-related products and services is increasing developments, thereby rising the demand for the genome editing market in the North America region.

The North America genome editing market is segmented based on technology, application, and end user. Based on technology, the market is segmented into CRISPR, TALEN, antisense, and others. In 2021, CRISPR segment held the largest share in the market. The CRISPR is associated with the Cas genes essential for adaptive immunity in selected bacteria and archaea. The CRISPR enables the organisms to respond to changes and eliminate invading genetic material. There are types of CRISPR mechanisms that have been adopted for genome-editing protocols, including wild-type Cas9, mutated Cas9, and nuclease-deficient Cas9. The CRISPR Cas9 is faster, cheaper, and more accurate than the other technologies of DNA editing and is used for wide applications. It is considered to be the simplest, most versatile, and precise method of genetic manipulation. The companies that offer CRISPR are Sangamo Therapeutics, Editas Medicine, Thermo Fisher Scientific, and Horizon Discovery Groups. Due to the simple, fast, and accurate properties of CRISPR, the market for this segment is growing at the fastest rate.

The overall North America genome editing market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining overview and forecast for the North America genome editing market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and to gain more analytical insights into the topic. The participants typically involved in this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the North America genome editing market. THERMO FISHER SCIENTIFIC INC., MERCK KGaA, Lonza, Horizon Discovery Group plc., Integrated DNA Technologies, GenScript, New England Biolabs, Eurofins Scientific, CRISPR Therapeutics, and Editas Medicine are among the leading companies in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America genome editing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America genome editing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the genome editing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution